{"title":"第14届帕金森氏病和运动障碍国际大会。","authors":"Donald Grosset, Andrew Grosset","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The 14th International Congress of Parkinson's Disease and Movement Disorders, held in Buenos Aires, included topics covering new therapeutic developments in the field of Parkinson's disease and other movement disorders. This conference report highlights selected presentations on drug treatments for movement disorders, including safinamide (Merck Serono SA), PYM-50028 (Phytopharm plc), droxidopa, pardoprunox (Abbott Laboratories); treatment considerations for dystonia; exploiting existing drugs for new indications; and using genetics to assess drug therapy responses.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 8","pages":"539-42"},"PeriodicalIF":0.0000,"publicationDate":"2010-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Movement Disorder Society--14th International Congress of Parkinson's Disease and Movement Disorders.\",\"authors\":\"Donald Grosset, Andrew Grosset\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The 14th International Congress of Parkinson's Disease and Movement Disorders, held in Buenos Aires, included topics covering new therapeutic developments in the field of Parkinson's disease and other movement disorders. This conference report highlights selected presentations on drug treatments for movement disorders, including safinamide (Merck Serono SA), PYM-50028 (Phytopharm plc), droxidopa, pardoprunox (Abbott Laboratories); treatment considerations for dystonia; exploiting existing drugs for new indications; and using genetics to assess drug therapy responses.</p>\",\"PeriodicalId\":55031,\"journal\":{\"name\":\"Idrugs\",\"volume\":\"13 8\",\"pages\":\"539-42\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Idrugs\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Idrugs","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The Movement Disorder Society--14th International Congress of Parkinson's Disease and Movement Disorders.
The 14th International Congress of Parkinson's Disease and Movement Disorders, held in Buenos Aires, included topics covering new therapeutic developments in the field of Parkinson's disease and other movement disorders. This conference report highlights selected presentations on drug treatments for movement disorders, including safinamide (Merck Serono SA), PYM-50028 (Phytopharm plc), droxidopa, pardoprunox (Abbott Laboratories); treatment considerations for dystonia; exploiting existing drugs for new indications; and using genetics to assess drug therapy responses.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
